VasoDynamics Receives UK-Taiwan Collaborative R&D Grant
VasoDynamics receives Grant to Progress Organ-on-Chip Technology with Partner Genenet
25th November 2024 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that it has been awarded a significant UK-Taiwan Collaborative R&D Grant from Innovate UK and Taiwan’s Department of Industrial Technology, MOEA. This funding will support an international collaboration in partnership with Genenet, Anntond Ind Co Ltd, Pythia Biotech Ltd on groundbreaking R&D efforts to advance organ-on-chip technology for high-efficiency real-time monitoring in microphysiological systems.
Ningfeng Fiona Li, CEO of VasoDynamics, said:
“VasoDynamics are delighted to be part of this Innovation UK Grant consortium to contribute to the innovation and development of this new groundbreaking technology. We are looking forward to taking this opportunity to participate in improving the AI-embedded toxicity screening technology to modernise and accelerate our drug discovery and validation process.”
For enquiries, please contact:
Dr Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk
Gary Bower, COO
gary.bower@vasodynamics.co.uk
Notes to Editors:
About VasoDynamics
VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.
